Myriad Presents Data at AACR on PTEN's Ability to Predict Prostate Cancer Outcomes
April 21, 2010
Myriad Presents Data at AACR on PTEN's Ability to Predict Prostate Cancer Outcomes
Data presented by Myriad at AACR support the "hypothesis that PTEN status predicts outcome after radical prostatectomy, and suggest further, that PTEN may be a clinically important molecular marker for defining aggressive prostate cancer."
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Medicare Administrator Issues Draft Decision Adding Myriad's Prolaris Test to Non-covered Service
September 24, 2012 / GenomeWeb Daily News - Continuing Push to Diversify Offerings, Myriad Licenses Chronix's Early Cancer Detection Technology
May 11, 2011 / Pharmacogenomics Reporter - Myriad 'Aggressively' Eyeing M&A, Companion Dx Deals, Euro Opportunities in FY 2011
August 11, 2010 / Pharmacogenomics Reporter - Myriad Outlines Marketing, Payment Plans to Counter Weak Economy, Raises Test Prices
May 5, 2010 / Pharmacogenomics Reporter - Prostate Cancer MDx Competition Heating Up; New Data from Genomic Health, Myriad
May 15, 2013 / Pharmacogenomics Reporter